Inhibin by Immunohistochemistry

Also known as: INHIBI IHC

Clinical Use

Use

The Inhibin by Immunohistochemistry test is primarily used in the evaluation of adrenal tumors, gonadal stromal tumors, and other conditions where it may serve as a sensitive and specific marker for the presence of inhibin. This test has particular significance in identifying ovarian sex cord-stromal tumors and is instrumental in diagnosing inhibin-secreting tumors. It helps in distinguishing these from other tumor types, contributing to accurate histological classification and aiding in the management and therapeutic decision-making for affected patients.

Special Instructions

Not provided.

Limitations

The performance characteristics of this test were determined by ARUP Laboratories. It has not been cleared or approved by the FDA, and its results should be correlated with other clinical and laboratory data available to the physician. Unacceptable conditions for test processing include non-representative tissue types and depleted specimens, which may lead to false results or inability to complete the test accurately. This test, performed as a stain and return service, may not always detect all inhibin-secreting tumors, and confirmatory tests may be necessary.

Test Details

New York Approved

Methodology

Immunoassay (IHC)

Biomarkers

Inhibin

Protein

IHC

Expression • Ordinal Score (e.g., TPS, CPS, H-score)

LOINC Codes

Result Codes

94736-6 - Tissue block ID Spec

Result Turnaround Time

1-3 days

Specimen

Tissue (FFPE)

Volume

Not provided

Minimum Volume

2 slides

Container

tissue transport kit

Collection Instructions

Formalin fix in 10 percent neutral buffered formalin and paraffin embed the specimen. Transport tissue block or 5 unstained, positively charged slides. Protect from excess heat.